Deerfield Management Company, L.P. (Series C) Nuvalent, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Nuvalent, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 19,991,024 shares of NUVL stock, worth $1.74 Billion. This represents 38.02% of its overall portfolio holdings.
Number of Shares
19,991,024
Previous 19,991,024
-0.0%
Holding current value
$1.74 Billion
Previous $1.52 Billion
34.85%
% of portfolio
38.02%
Previous 31.83%
Shares
2 transactions
Others Institutions Holding NUVL
# of Institutions
209Shares Held
59.5MCall Options Held
450KPut Options Held
619K-
Paradigm Biocapital Advisors LP New York, NY5MShares$434 Million18.43% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.13MShares$359 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$263 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.98MShares$259 Million7.96% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA2.7MShares$234 Million49.52% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.73B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...